Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials

11 Jun 2009

Abstract excerpt

The recently introduced human papillomavirus (HPV) prophylactic vaccines are the first widely approved vaccines specifically designed to prevent a sexually transmitted infection and are only the second (after the hepatitis B virus vaccine) designed to prevent human cancer, in this case cervical cancer and several other anogenital and head and neck cancers. The antigens in the HPV vaccines are naked icosohedral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to Cervical Cancer and HPV Research
Share to Hepatitis B Virus Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19519255
DOI: 10.1086/599988

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine TrialsPMID 19519255Read ↗

Cervarix™ – a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancerSemantic proximity Read ↗

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle StructuresSemantic proximity Read ↗

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?Semantic proximity Read ↗

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in MiceSemantic proximity Read ↗

Human papillomavirus vaccinesSemantic proximity Read ↗

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine CandidatesSemantic proximity Read ↗

Virus‑like particles as a vaccine delivery system: Myths and factsSemantic proximity Read ↗

Genital human papillomavirus infection.Semantic proximity Read ↗

A universal virus-like particle-based vaccine for human papillomavirus: Longevity of protection and role of endogenous and exogenous adjuvantsSemantic proximity Read ↗

Potential of Recombinant Chimeric HPV16 L1/L2 VLPs Produced by Distinct Cell Lineages Such as Prophylactic Nanovaccine and Therapeutic Drug NanocarriersSemantic proximity Read ↗

[What clinicians should know about human papilloma virus vaccines].Semantic proximity Read ↗

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.